SIGLEC1 and melanoma: By conjugating T cell epitopes from melanoma-associated antigens such as Trp2, gp100, and MART-1 to antibodies specific for mouse and human CD169, strong T cell responses were obtained in both mouse models and human cell studies, suggesting broad translational potential [189,190].